Abliva AB (publ) (0QDU.L)

0.2525 -0.0065 (-2.51%) At close: 10:26AM BST

Abliva AB (publ)

Medicon Village
Lund 223 81
Sweden
46 4 62 75 62 20
https://abliva.com

Sector(s): 
Industry: 
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ellen K. Donnelly Ph.D.	Chief Executive Officer	4.97M	N/A	1974
Ms. Catharina Jz Johansson	Deputy CEO, CFO & VP of Investor Relations	N/A	N/A	1967
Dr. Eskil Elmér M.D., Ph.D.	Chief Scientific Officer & VP of Discovery	247k	N/A	1970
Daniel Schale	Director of Communications	N/A	N/A	N/A
Dr. Magnus Hansson	Chief Medical Officer and VP of Preclinical & Clinical Development	N/A	N/A	1976
Mr. Dag Nesse	Vice President of Clinical Operations	N/A	N/A	N/A
Dr. Lars Vedin	Consultant	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Corporate governance

Abliva AB (publ)’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.